



Article

Moderate COVID-19: Clinical Trajectories and Predictors of Progression and Outcomes

Apostolos G. Pappas ^{1,2,*}, Andreas Panagopoulos ^{2,3} , Artemis Rodopoulou ², Michaella Alexandrou ¹, Anna-Louiza Chaliasou ^{2,4}, Konstantinos Skianis ⁵, Eleftheria Kranidioti ^{2,3}, Eleftheria Chaini ^{6,7}, Ilias Papanikolaou ^{6,7}  and Ioannis Kalomenidis ^{1,2}

- ¹ 1st Department of Critical Care & Pulmonary Service, School of Medicine, National and Kapodistrian University of Athens, “Evangelismos” General Hospital, 10676 Athens, Greece
 - ² COVID-19 Unit, “Evangelismos” General Hospital, 10676 Athens, Greece
 - ³ 3rd Department of Internal Medicine, “Evangelismos” General Hospital, 10676 Athens, Greece
 - ⁴ 4th Department of Internal Medicine, “Evangelismos” General Hospital, 10676 Athens, Greece
 - ⁵ Data Science & Mining Team, École Polytechnique, 91120 Paris, France
 - ⁶ Pulmonary Department, Corfu General Hospital, 49100 Corfu, Greece
 - ⁷ COVID-19 Unit, Corfu General Hospital, 49100 Corfu, Greece
- * Correspondence: apo.pappas88@gmail.com



Citation: Pappas, A.G.; Panagopoulos, A.; Rodopoulou, A.; Alexandrou, M.; Chaliasou, A.-L.; Skianis, K.; Kranidioti, E.; Chaini, E.; Papanikolaou, I.; Kalomenidis, I. Moderate COVID-19: Clinical Trajectories and Predictors of Progression and Outcomes. *J. Pers. Med.* **2022**, *12*, 1472. <https://doi.org/10.3390/jpm12091472>

Academic Editor: Miguel A Ortega

Received: 12 August 2022

Accepted: 2 September 2022

Published: 8 September 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Background: Patients with COVID-19 commonly present at healthcare facilities with moderate disease, i.e., pneumonia without a need for oxygen therapy. Aim: To identify clinical/laboratory characteristics of patients with moderate COVID-19, which could predict disease progression. Methods: 384 adult patients presented with moderate COVID-19 and admitted to two hospitals were retrospectively evaluated. In a multivariate analysis gender, age, BMI, Charlson Comorbidity Index (CCI) and National Early Weaning Score 2 were treated as co-variables. The development of hypoxemic respiratory failure, intubation rate and risk of death were considered as dependent variables. Estimated values are presented as odds-ratio (OR) with 95% confidence interval (CI). Results: Most of the patients were male (63.28%) with a mean (standard deviation) age of 59 (16.04) years. Median (interquartile range) CCI was 2 (1–4). A total of 58.85% of the patients developed respiratory failure; 6.51% were intubated, and 8.85% died. The extent of pneumonia in chest X-ray (involvement of all four quartiles) [OR 3.96 (1.18–13.27), $p = 0.026$], respiratory rate [OR 1.17 (1.05–1.3), $p = 0.004$], SatO₂ [OR 0.72 (0.58–0.88), $p = 0.002$], systolic blood pressure [OR 1.02 (1–1.04), $p = 0.041$] and lymphocyte count [OR 0.9993 (0.9986–0.9999), $p = 0.026$] at presentation were associated with the development of respiratory failure. The extent of pneumonia [OR 26.49 (1.81–387.18), $p = 0.017$] was associated with intubation risk. Age [OR 1.14 (1.03–1.26), $p = 0.014$] and the extent of pneumonia [OR 22.47 (1.59–316.97), $p = 0.021$] were associated with increased risk of death. Conclusion: Older age, the extent of pneumonia, tachypnea, lower SatO₂, higher systolic blood pressure and lymphopenia are associated with dismal outcomes in patients presenting with moderate COVID-19.

Keywords: COVID-19; SARS-CoV-2; moderate disease; risk factors

1. Key Messages

What is the key question? What are the clinical/laboratory characteristics and the predictors of disease progression in patients with moderate COVID-19 (i.e., patients with COVID-19 pneumonia and without respiratory failure)?

Which are the main findings? Older age, tachypnea, lower SatO₂, higher systolic blood pressure, lymphopenia and the extent of pneumonia in a chest X-ray at presentation were independently associated with dismal outcomes in patients with moderate COVID-19.

Why read on? The present study focuses on patients with moderate COVID-19 at presentation and may help to identify those patients at risk for disease progression and hospitalization.

2. Introduction

Nearly two years after COVID-19 first appeared in Wuhan, China, [1] SARS-CoV-2 infection still poses a major threat worldwide. Since multiple new variants have emerged and vaccination programs have not met their goals [2], morbidity and mortality due to COVID-19 are expected to remain high [3]. Many regions will probably face a resurgence of COVID-19 [4], which will cause overwhelming pressure to hospital systems [3]. In an effort to make optimal use of hospital resources, it is crucial to be able to predict disease progression [3,5]. This is particularly important for patients presenting with moderate disease (patients with clinical and/or radiographical evidence of pneumonia with no need for supplemental oxygen, i.e., $\text{SpO}_2 \geq 90\%$ on room air) [6], since decisions on their admission to the hospital are intriguing. Unfortunately, the currently available prognostic tools are suboptimal in predicting clinical deterioration, especially in the medium-risk population [7,8].

In the present study, we analyzed data collected from patients presenting to the emergency department (ED) with moderate COVID-19 [6] and admitted to the hospital. Our aim was to describe their clinical course and identify factors associated with disease progression and outcomes. We hypothesized that certain clinical and/or laboratory features available at the time of first evaluation of these patients exhibit important predictive values.

3. Patients and Methods

We retrospectively evaluated 384 consecutive patients with age > 18 and confirmed SARS-CoV-2 infection by quantitative RT-PCR in nasopharyngeal swab specimens, who presented with moderate COVID-19 [6] and were admitted to the hospital. Among them, 41 patients were admitted to the COVID-19 ward of “Corfu General Hospital”, Corfu, Greece, between 1 September 2020 and 30 April 2021, while 343 were admitted to the COVID-19 ward of “Evangelismos” General Hospital, Athens, Greece, between 1 September 2020 and 31 December 2020. Patients’ demographical and clinical characteristics, laboratory values and final outcomes were retrieved from medical records. Quantitative evaluation of chest X-ray pathological lesions was performed as described elsewhere [9]. Due to the retrospective nature of the study, an informed consent was not obtained by the patients. The study was approved by the Ethics Committees of the Hospitals. Protocol numbers: 44 (25-2-2021) and 1615B (13-4-2021).

Statistical Analysis

Quantitative variables with Gaussian distribution are presented as mean (standard deviation-SD) and were analyzed with Student’s T-test or one-way analysis of variance (ANOVA). Non-parametric quantitative variables are presented as median (interquartile range-IQR) and were analyzed using the Mann–Whitney U-Test. Qualitative variables are presented as n (%) and were analyzed with a Chi-square test. All variables were evaluated using two-tailed tests. A univariate analysis was performed with the development of hypoxemic respiratory failure, intubation and death being the dependent variables. Subsequently, the statistically significant variables in univariate analysis were evaluated in a multiple logistic regression model with gender, age, body mass index (BMI), Charlson comorbidity index (CCI) [10] and national early weaning score (NEWS) 2 [8] treated as covariates, while the development of respiratory failure, intubation and death were considered as dependent variables. Calculated estimates are shown as odds ratios (OR), with 95% confidence intervals (CI). For quantitative variables, OR reflects changes per given unit. The statistical analysis and regression tasks were performed with Python and open-source libraries: scikit-learn and stats models.

4. Results

4.1. Patients' Clinical and Laboratory Characteristics

A total of 384 patients with moderate COVID-19 at presentation were evaluated, 243 of whom (63.28%) were male. Most of them were of European origin (83.07%) with a mean (SD) age of 59 (16.04) years. The median (IQR) CCI score was 2 (1–4). The median (IQR) number of days from symptom onset to presentation was 6 (4–8). The median (IQR) NEWS2 score at presentation was 2 (1–5). Comorbidities, symptoms/signs and laboratory values are depicted in Tables 1–3.

Table 1. Clinical and epidemiological characteristics of patients on admission.

BMI		Coronary Artery Disease	41 (10.68)	Any Cancer	26 (6.77)
<18	1 (0.26)	Atrial Fibrillation	23 (6)	Active	16 (4.18)
18–24.9	191 (50.39)	COPD	11 (2.86)	History	10 (2.6)
25–30	118 (31.13)	Asthma	17 (4.43)	Chronic Kidney Disease	
>30	69 (18.2)	Tuberculosis	1 (0.26)	CKD without dialysis	20 (5.2)
Smoking Status		Immuno-supression	25 (6.51)	CKD-dialysis	9 (2.34)
Never	282 (73.44)	Diabetes mellitus	81 (21.09)	Cerebrovascular disease	18 (4.69)
Current	35 (9.11)	Type I	12 (3.13)	Chronic liver disease	12 (3.12)
Former	67 (17.45)	Type II	69 (17.97)	HBV	6 (1.56)
Hypertension	129 (33.59)	Connective tissue disease	17 (4.43)	HCV	4 (1.04)
				Other	2 (0.52)

Data are presented as n (%). BMI: body mass index; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; HBV: hepatitis virus B; HCV: hepatitis virus C.

Table 2. Symptoms and signs on admission.

Sore throat/nasal congestion	27 (7.03)	Malaise	114 (29.69)	SatO₂%	95.7 (94–97)
Cough	221 (57.55)	Headache	35 (9.11)	Systolic BP mmHg	120 (110–130)
Fever	324 (84.37)	Chest pain	44 (11.46)	Chest X-ray quartiles	
Diarrhea/Vomiting	69 (17.97)	Abdominal pain	25 (6.51)	1	74 (19.27)
Dyspnoea	73 (19.01)	Temperature °C	37 (36.6–38)	2	173 (45.05)
Confusion	14 (3.64)	RR (breaths/min)	20 (18–22)	3	71 (18.49)
Myalgia	55 (14.32)	BPM	87 (78–97)	4	66 (17.19)

Quantitative variables are presented as median (inter-quartile range-IQR) and qualitative variables are presented as n (%). RR: respiratory rate; BPM: beats per minute; BP: blood pressure; SatO₂: oxygen saturation.

4.2. Treatments, Clinical Trajectories and Outcomes

The treatment of SARS-CoV-2 infection during patients' hospital stay was given in accordance to the national guidelines at the certain period of time (eody.gov.gr/en/covid-19/ accessed on 27 August 2020). Briefly, patients progressing to hypoxemic respiratory failure received therapy with intravenous (IV) dexamethazone and IV remdesivir (unless contraindicated). Most of them received antibiotic treatment (91.67%), with azithromycin being the most common antibiotic (72.39%). The majority of the patients received anticoagulants in a prophylactic dose (86.95%), mostly with subcutaneous (sc) low-molecular weight heparine (72.32%) and sc fondaparinux (20.63%). Some 3.92% received no anticoagulants due to hemorrhage or low platelet counts, and 8.88% received therapeutic anticoagulation due to chronic conditions (e.g., atrial fibrillation) or newly diagnosed venous thromboembolism. The median (IQR) number of hospitalization days was 10 (7–14.25). Major complications are described in Table 4.

Table 3. Laboratory values on admission.

WBC/μL	5670 (4525–7200)	ESR mm/h	35 (21–50)	ALP IU/L	60 (48–77)
Neutrophils/μL	3865 (2860–5464)	Glucose mg/dL	108 (97.5–130)	γGT IU/L	29 (17–51)
Lymphocytes/μL	1210 (895–1580)	Urea mg/dL	30 (23.5–40)	Billirubin mg/dL	0.47 (0.35–0.6)
Platelets X1000/μL (IQR)	187 (152–241.5)	Creatinine mg/dL	0.9 (0.8–1.1)	LDH IU/L	301 (235–375)
HgB g/dL	14 (13–15)	Na⁺ mmol/L	138 (135–140)	C-Reactive Protein mg/dL	4.3 (1.5–8.75)
PT sec	12.6 (12–13.3)	K⁺ mmol/L	4.3 (3.9–4.7)	CPK IU/L	104 (68–196.5)
aPTT sec	31.8 (28.87–35.62)	Corrected Ca²⁺	8.87 (8.6–9.18)	Cardiac troponinepg/mL	8 (4–15)
Fibrinogen mg/dL	521 (446–627)	Albumin g/dL	4 (3.6–4.2)	PaO₂ mmHg	70 (64–80)
D-Dimers μg/mL	0.68 (0.46–1.2)	AST IU/L	31 (23–45)	P/F Ratio	331 (301.5–381)
Ferritin ng/mL	270 (149–540.3)	ALT IU/L	24 (16.5–38)	Lactate mmol/L	1 (0.8–1.25)

Values are presented as median (interquartile range-IQR). WBC: white blood cells; HgB: hemoglobin; PT: prothrombin time; aPTT: activated partial thromboplastin time; ESR: erythrocyte sedimentation rate; AST: aspartate transaminase; ALT: alanine transaminase; ALP: alkaline phosphatase; γ GT: gamma-glutamyl transferase; LDH: lactate dehydrogenase; CPK: creatine phosphokinase.

Table 4. Major complications during hospitalization.

Hospital-Acquired Infection	52 (13.65)	Liver Dysfunction		Cardiac	25 (6.51)
Pneumonia	17 (4.46)	AST/ALT elevation	52 (13.54)	pericarditis	6 (1.56)
UTI	20 (5.25)	γ GT/ALP elevation	11 (2.86)	arrhythmia	11 (2.86)
Bacteremia/ Fungemia	23 (6.04)	both	36 (9.37)	ACS	3 (0.8)
C. Dif.	6 (1.57)	Thromboembolism		myocarditis	3 (0.8)
Shock	25 (6.51)	DVT	3 (0.8)	2 or more	2 (0.52)
AKI	23 (5.99)	PE	8 (2.08)	Ketoacidosis	3 (0.8)

Values are presented as n (%). UTI: urinary tract infection; C. Dif: clostridium difficile colitis; AST: aspartate transaminase; ALT: alanine transaminase; ALP: alkaline phosphatase; γ GT: gamma-glutamyl transferase; ACS: acute coronary syndrome; AKI: acute kidney injury; DVT: deep venous thrombosis; PE: pulmonary embolism.

Within 2 (1–4) days of hospital admission, 226 patients (58.85%) deteriorated and developed hypoxemic respiratory failure, requiring supplemental oxygen. A total of 49 (12.76%) of patients required therapy with high-flow nasal oxygen (HFNO), and 27 (7.03%) were treated with non-rebreathing masks (NRM). Subsequently, 41 patients (10.68%) were admitted to the intensive care unit (ICU), and 25 (6.51%) patients required endotracheal intubation and mechanical ventilation. A total of 21 of them eventually died of respiratory failure or ICU-related complications. Another 13 patients with Do-Not-Intubate (DNI) orders died from respiratory failure. Overall, 34 patients (8.85%) died.

4.3. Link between Clinical/Laboratory Features and Disease Progression or Outcomes

The association between clinical/laboratory features at presentation and the development of respiratory failure, intubation and death were assessed using univariate and multivariate analysis. Independent variables significantly associated with at least one dependent variable in the univariate analysis are presented in Supplementary Tables S1–S3. Significant values were further evaluated in a multiple regression model, with gender, age, BMI, CCI and NEWS2 serving as co-variates. The involvement of all four chest X-ray quartiles [OR 3.96 (1.18–13.27), $p = 0.026$], systolic blood pressure [OR 1.02 (1–1.04), $p = 0.041$], respiratory rate [OR 1.17 (1.05–1.3), $p = 0.004$], SatO₂ [OR 0.72 (0.58–0.88), $p = 0.002$] and blood lymphocyte count [OR 0.9993 (0.9986–0.9999), $p = 0.026$] at presentation were independent predictors of the development of hypoxemic respiratory failure (Figure 1A). The involvement

of all four chest X-ray quartiles [OR 26.49 (1.81–387.18), $p = 0.017$] was also independently associated with intubation risk (Figure 1B). Finally, age [OR 1.14 (1.03–1.26), $p = 0.014$] and involvement of all four chest X-ray quartiles [OR 22.47 (1.59–316.97), $p = 0.021$] were independent predictors of death (Figure 1C). Of note, only the size of pneumonia on chest imaging was consistently associated with all three different outcomes in the multiple regression analysis.




Figure 1. Multivariate analysis-Forest Plots. Statistically significant variables in univariate analysis were evaluated in a multiple logistic regression model with gender, age, body mass index (BMI), Charlson comorbidity index (CCI), and national early weaning score (NEWS) 2 treated as covariates, while progression to respiratory failure, intubation and death were considered as dependent variables: (A) involvement of all four chest X-ray quartiles ($p = 0.026$), higher systolic blood pressure [mmHg, ($p = 0.041$)], higher respiratory rate [breaths per min, ($p = 0.004$)], lower SatO₂ [%], ($p = 0.002$)] and lymphopenia [cells/ μ L, ($p = 0.026$)] were independent risk factors of the development of respiratory failure; v (B) involvement of all four chest X-ray quartiles ($p = 0.017$) was an independent predictor of intubation; (C) older age [years, ($p = 0.014$)] and involvement of all four chest X-ray quartiles ($p = 0.021$) were independent predictors of death. Calculated estimates are shown as odds ratios (OR), with 95% confidence intervals (CI). For quantitative variables, OR reflects changes per given unit. p -values < 0.05 were consider significant.

5. Discussion

In this retrospective analysis, we evaluated 384 patients admitted with moderate COVID-19 [6] to two different hospitals in Greece. Most of the patients were of European origin, with a mean age of 59 years and a normal BMI. Arterial hypertension was the most frequent comorbidity, and the median (IQR) CCI was 2 (1–4). Over half of the patients developed hypoxemic respiratory failure, at a median (IQR) 2 (1–4) days after admission, with 10.68% requiring ICU admission and 6.51% requiring invasive mechanical ventilation; 8.85% of patients died. Multiple regression analysis revealed that: (1) involvement of all four chest X-ray quartiles, high systolic blood pressure and respiratory rate, low SatO₂ and low number of blood lymphocytes at presentation were significantly associated with high risk of development of respiratory failure; (2) involvement of all four chest X-ray quartiles was significantly associated with increased risk of intubation; and (3) older age and the involvement of all four chest X-ray quartiles were significantly associated with increased risk of death.

To our knowledge, this is the first study focusing entirely on patients with moderate COVID-19 at presentation. Although these patients were not in urgent need for hospital admission, they were admitted to both hospitals during the study period when presenting with significant hypoxemia (SaO₂ ≤ 94%) or multiple/severe co-morbidities. This approach was mainly based on the difficulty to estimate the individual patient risk, especially if one considers that SARS-CoV-2 infection is characterized by a highly variable clinical course, and worsening of respiratory function may appear several days after symptom onset [11]. While the high rate of rapid (usually within 48 h after admission) progression to respiratory failure (58.85%) observed in our cohort partly justifies this practice, still more than 40% of patients could be treated as outpatients, in this way reducing patient discomfort and pressure on the hospital system during epidemic surges [2,4].

In an effort to predict clinical deterioration, several prognostic tools have been previously developed for COVID-19 [7,8], but they appear suboptimal when applied to medium-risk populations [7]. Similarly, we observed that CCI and NEWS2 scores were not associated with any of the outcomes tested in the multiple regression analysis. A common characteristic of these clinical severity scores is that they do not take into account the size of pneumonia on chest imaging, a feature that in our study was consistently associated with the development of respiratory failure, the risk of intubation and death. The close link between lung imaging findings and the disease progression and outcomes is in agreement with previous reports in COVID-19 patients (with varying disease severity), demonstrating that outcomes could be predicted by baseline chest radiography [9,12] and bedside lung ultra-sonography [13]. Thus, patients with extensive bilateral pneumonia at presentation should most likely be admitted to the hospital, even if they have not yet developed respiratory failure.

Apart from a chest X-ray, other respiratory parameters independently associated with the development of hypoxemic respiratory failure were lower SatO₂ and higher respiratory rate at presentation. In contrast, dyspnea was not associated with disease progression, more likely reflecting the fact that several COVID-19 patients do not report this symptom in spite of the severity of the respiratory disease [14]. The association of higher systolic blood pressure with the development of respiratory failure comes in line with previous reports describing that patients on anti-hypertensive medication exhibited lower risk of in-hospital mortality [15]. Similarly, the severity of lymphopenia [16] and older age [17] have been previously well-characterized predictors of outcomes in unselected patients with SARS-CoV-2 infection.

Apart from its retrospective design, an important limitation of our study is the fact that it was conducted in hospitalized patients, meaning that our observations may not apply to the whole spectrum of patients who are seeking medical care and are suffering from COVID-19 pneumonia without respiratory failure. Furthermore, the time when a patient decides to seek medical help relies mainly on subjective reasons, and this may be considered as a possible bias. However, the fact that we probably investigated patients

with “high risk” SARS-CoV-2 infection (for which the decision for hospitalization appears to be a realistic though doubtful choice) supports the clinical relevance of our findings. Far from being conclusive, our observations pave the way for prospective studies on patients with COVID-19 pneumonia (but without respiratory failure) seeking care in EDs or primary care facilities, which will define admission criteria for moderate COVID-19.

In conclusion, we herein described the clinical, epidemiological and laboratory characteristics of patients with moderate COVID-19 at presentation, and we demonstrated that the severity of respiratory disease (involvement of all four chest X-ray quartiles, higher respiratory rate and lower SatO₂), older age, higher systolic blood pressure and lower blood lymphocyte count are associated with the development of respiratory failure and high risk of intubation or death in this distinct population. Although the decision for hospital admission is personalized and relies mainly on the physician’s clinical judgment, the presence of one or more of the aforementioned risk factors for the development of respiratory failure may help physicians identify patients with moderate COVID-19, who are in need of hospitalization. However, our study is “hypothesis generating” and validation of our findings with prospective studies is further required.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/jpm12091472/s1>, Table S1: Univariate analysis-Association with development of respiratory failure. Table S2: Univariate analysis-Association with intubation. Table S3: Univariate analysis-Association with death.

Author Contributions: A.G.P. contributed to the data collection and wrote the first draft; A.P., A.R., M.A., A.-L.C., E.K., E.C. and I.P. contributed to different parts of data collection and reviewed the manuscript; K.S. conducted the statistical analysis and reviewed the manuscript; I.K. conceived the idea, designed the study, oversaw the data collection and critically contributed in writing and reviewing the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: The current project received no funding.

Institutional Review Board Statement: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committees of the Hospitals. Protocol numbers: 44 (25-2-2021) and 1615B (13-4-2021).

Informed Consent Statement: Patient consent was waived due to the retrospective nature of the study.

Data Availability Statement: Data are available upon contact with the corresponding author.

Acknowledgments: The publication of the present article was funded by the National and Kapodistrian University of Athens, Greece (Special Research Fund Account).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* **2020**, *382*, 727–733. [[CrossRef](#)]
2. Fontanet, A.; Autran, B.; Lina, B.; Kieny, M.P.; Karim, S.S.A.; Sridhar, D. SARS-CoV-2 variants and ending the COVID-19 pandemic. *Lancet* **2021**, *397*, 952–954. [[CrossRef](#)]
3. CDC COVID-19 Forecasts: Deaths, Updated 18 August 2021. Available online: <https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/forecasting-us.html> (accessed on 1 September 2020).
4. Vahidy, F.S.; Drews, A.L.; Masud, F.N.; Schwartz, R.L.; Askary, B.; Boom, M.L.; Phillips, R.A. Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area. *JAMA* **2020**, *324*, 998–1000. [[CrossRef](#)] [[PubMed](#)]
5. Truog, R.D.; Mitchell, C.; Daley, G.Q. The Toughest Triage—Allocating Ventilators in a Pandemic. *N. Engl. J. Med.* **2020**, *382*, 1973–1975. [[CrossRef](#)] [[PubMed](#)]
6. World Health Organization. *Clinical Management of COVID-19: Interim Guidance 27 May 2020*; Table 2; World Health Organization: Geneva, Switzerland, 2020; Chapter 3, p. 13.

7. Al Hassan, H.; Cocks, E.; Jesani, L.; Lewis, S.; Szakmany, T. Clinical Risk Prediction Scores in Coronavirus Disease 2019: Beware of Low Validity and Clinical Utility. *Crit. Care Explor.* **2020**, *2*, e0253. [[CrossRef](#)] [[PubMed](#)]
8. Zhang, K.; Zhang, X.; Ding, W.; Xuan, N.; Tian, B.; Huang, T.; Zhang, Z.; Cui, W.; Huang, H.; Zhang, G. The Prognostic Accuracy of National Early Warning Score 2 on Predicting Clinical Deterioration for Patients With COVID-19: A Systematic Review and Meta-Analysis. *Front. Med.* **2021**, *8*, 699880. [[CrossRef](#)]
9. Mylona, E.; Evangelia, M.; Eleftheria, K.; Vasilios, V.; Vana, S.; Vissaria, S.; Evangelos, B.; Ioannis, K. Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region. *Pathog. Glob. Health* **2021**, *115*, 243–249. [[CrossRef](#)]
10. Kuswardhani, R.T.; Henrina, J.; Pranata, R.; Lim, M.A.; Lawrensia, S.; Suastika, K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. *Diabetes Metab. Syndr.* **2020**, *14*, 2103–2109. [[CrossRef](#)] [[PubMed](#)]
11. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **2020**, *395*, 497–506. [[CrossRef](#)]
12. Sverzellati, N.; Ryerson, C.J.; Milanese, G.; Renzoni, E.A.; Volpi, A.; Spagnolo, P.; Bonella, F.; Comelli, I.; Affanni, P.; Veronesi, L.; et al. Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. *Eur. Respir. J.* **2021**, *58*, 2004188. [[CrossRef](#)] [[PubMed](#)]
13. Rubio-Gracia, J.; Giménez-López, I.; Garcés-Horna, V.; López-Delgado, D.; Sierra-Monzón, J.L.; Martínez-Lostao, L.; Josa-Laorden, C.; Ruiz-Laiglesia, F.; Pérez-Calvo, J.I.; Crespo-Aznarez, S.; et al. Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: A prospective non interventional study. *Eur. Respir. J.* **2021**, *58*, 2004283. [[CrossRef](#)] [[PubMed](#)]
14. Couzin-Frankel, J. The mystery of the pandemic's 'happy hypoxia'. *Science* **2020**, *368*, 455–456. [[CrossRef](#)] [[PubMed](#)]
15. Rosenthal, N.; Cao, Z.; Gundrum, J.; Sianis, J.; Safo, S. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. *JAMA Netw. Open* **2020**, *3*, e2029058, Erratum in *JAMA Netw Open.* **2021**, *4*, e2036103. [[CrossRef](#)] [[PubMed](#)]
16. Lee, J.; Park, S.-S.; Kim, T.; Lee, D.-G.; Kim, D.-W. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. *Cancers* **2021**, *13*, 471. [[CrossRef](#)] [[PubMed](#)]
17. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern. Med.* **2020**, *180*, 934–943, Erratum in *JAMA Intern. Med.* **2020**, *180*, 1031. [[CrossRef](#)] [[PubMed](#)]